

## **Dimitris Stellas**

Associate Researcher  
Institute of Chemical Biology

Phone: +30.210. 7273830

Fax: +30.210.7273831

E-mail: dstellas@eie.gr

Website: www.eie.gr

### **Professional Appointments (Academia – Industry)**

- Jan2020-present: **Associate Researcher**  
National Hellenic Research Foundation
- Jan2017-Jan2020: **Research Fellow**  
Center for Cancer Research (CCR), National Cancer Institute (NCI) at National Institutes of Health (NIH) USA.
- May2011-Jan2017: **Postdoctoral Researcher**  
Laboratory of Cancer Biology, Biomedical Research Foundation of the Academy of Athens, (BRFAA)
- Aug2010-  
May2011: **Military Service/ Specialized Researcher**  
Pathology department in the 401 General Military Hospital
- Jan2009-  
Aug2010: **Research Assistant/ Postdoctoral Researcher**  
Laboratory of Chemical Carcinogenesis and Genetic Toxicology, Institute of Biological Research & Biotechnology, National Hellenic Research Foundation (NHRF)
- Sep2003-  
Jan2009: **Research Assistant**  
Laboratory of Cellular and Molecular Oncology, Biochemistry Department, Hellenic Pasteur Institute (HPI)

### **Academic Achievements**

- Jan2004-Jan2010: **PhD in Medicine. Classification: 10/10 (magna cum laude)**  
**Department of Biological Chemistry, Athens Medical**

### **School, Greece**

*PhD thesis: Study of heat shock protein 90 (HSP90) on cancer development*, Supervisor: Dr. A.G.Papavasileiou. The main work was performed under the supervision of Dr. E. Patsavoudi in the Lab of Molecular and Cellular Oncology of the Hellenic Pasteur Institute.

Oct1999-Sep2003: **B.Sc in Biology, Dept of Biology, University of Patras, Greece**

*BSc dissertation: Cloning of the human gene of bone morphogenetic protein 2 (BMP2) into pcdna3 vector and stable transfecting it into C2C12 human cell line.*

**Supervisor:** Professor A. G. Papavasileiou

Laboratory of Biochemistry, Patras Medical School, Greece

### **Awards**

Participation in Awarded presentations:

1. May 2015: 10th European Workshop in Drug Design, Siena, Italy. Best Poster presentation, poster title: "Structure- and ligand-based drug design studies for identification of novel Myc nhibitors". Maria-Elena Liosi, Dimitris Stellas, Argiris Efstratiadis, Zoe Cournia
2. 2011 Paxinos Award from Hellenic society for Neuroscience: PROX1 suppresses the proliferation of neuroblastoma cells via action in p27-KIP1and CDC25A. Iosifina-Petrina Foskolou, Dimitris Stellas, Ismini Rozani and Panagiotis Politis.
3. 2007: Best oral presentation award in the 3d Hellenic Anti carcinogenic Congress. Athens 26-29 April 2007. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Dimitris Stellas and Evangelia Patsavoudi.

### **Patents**

D. Stellas, Z. Cournia, C. Tamvakopoulos, A. Klinakis & A. Efstratiadis

Novel Compounds for use in treating or preventing cancerous diseases  
 European Patent Application number EP 15 175 918.0

### **Funding**

1. BioRad Grant, Evaluation of a novel platform for long non-coding RNAs derived from tissues of patients bearing pancreatic ductal adenocarcinoma, 2016 (D.Stellas PI)

2. Hellenic Company of Metastatic Liver Disease Grant, Patient derived xenografts for evaluation of novel drugs for pancreatic ductal adenocarcinoma, 2016 (D.Stellas PI)

3. Euronanomed 2 Grant, Self-assembling dendrimer based nanotheranostics to combat cancer, 2016 (C. Demetzos PI)

4. NIH NCI/RFA, Study of hetIL-15 effects on pancreatic ductal adenocarcinoma using KPC GEM mice, 2017 (G.Pavlakis PI)

5. NIH NCI/RFA, Co-administration of heterodimeric IL-15, anti-mesothelin antibodies and immunotoxins for treatment of Pancreatic Ductal Adenocarcinoma, 2018 (G.Pavlakis PI)

### **Membership**

Editorial board member for *Journal of Molecular Biochemistry*

Editorial board member for CPQ Cancer

American Association of Cancer Research (AACR)

American Society of Clinical Oncology (ASCO)

Society for Immunotherapy and Cancer (SITC)

Hellenic Union of Biochemical Researchers (HSBMB)

### **Invited Speaker**

Invited speaker: CANGENIN - High-throughput screens in genome integrity and cancer. Oxford May 24-28, 2010

Invited for training in Columbia University New York by Dr. Szabolcs on pathology of pancreas, 2012

Invited speaker in Mayo Clinic Rochester Minnesota by Dr. Van Deursen in the Kogold center of aging. 'Analysis of the S-phase arrest in mitotic instability', 2012

Invited speaker in Beth Israel Deaconess Medical Center, Harvard Medical School by Dr. Kotaridis, 'Modeling PIK3CA Oncogenic Mutations in Breast and Colon Cancers for the development of targeted Anticancer Drugs and Diagnostics', 2014

Invited speaker in the 21<sup>st</sup> Clinical Oncology congress in Hilton hotel Athens Greece, 'Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.' 2015

### **Mentoring & Teaching Activities**

100mentors partner

### **Thesis Committees & Supervision of Junior Researchers**

2015-2017: Supervision of Msc thesis of Ourania Fari, (entitled 'The involvement of c-MYC oncoprotein in immunological aspects of pancreatic cancer progression in mouse models')

Supervision of Msc thesis of Vassiliki Stravokefalou, entitled 'Study of the role of PIK3Ca gain of function mutations in Breast Cancer chemo-resistence, in vitro and in vivo.

2013-2014: Supervision of Msc thesis of Lambrini Tsoutsi, entitled: 'The role of Igf1 and Igf2 in the development of mouse embryos.'

Participation in the supervision of master 'rotation' students in BRFAA.

2004-2009: Invited speaker for the postgraduate and PhD-candidate lectures series of the Cellular Oncology and Biochemistry Laboratory, of the Hellenic Pasteur Institute.

2004-2009: Participation in the supervision of diploma theses of undergraduate and PhD students, Cellular Oncology and Biochemistry Laboratory, Hellenic Pasteur Institute.

2004-2005: Research Assistant, Dept. of Medical Instruments Technology, Technological Educational Institute of Athens. Participation of the reformation of Under Graduates' Schedule. Aiming the upgrade of an in vitro laboratory and in the same time to maintain its educational role.

**Peer-reviewed Research Publication List**

1. **Stellas**, D., Patsavoudi, E., and Vattis, D.: New educational material for in vitro laboratories. *WSEAS Transactions on Advances in Engineering Education* 2: 135-138.2005.
2. **Stellas**, D., Karameris, A., and Patsavoudi, E.: Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. *Clin. Cancer Res.* 13: 1831-1838. 2007.
3. Sidera, K. Gaitanou, M., **Stellas**, D., Gaitanou, M., Matsas, R., and Patsavoudi, E.: A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. *J. Biol. Chem.* 283: 2031-2041. 2008.
4. **Stellas**, D., El Hamidieh, A., and Patsavoudi, E.: Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. *BMC Cell Biol.* 11: 51. 2010.
5. **Stellas**, D. and Patsavoudi, E.: Inhibiting matrix metalloproteinases., an old story with new potentials for cancer treatment. *Anticancer Agents Med Chem.* 9: 707-717, 2012.
6. Foskolou, I.P., **Stellas**, D., Rozani, I., Lavigne, M.D., and Politis, P.K.: Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A. *Oncogene* 32: 947-960. 2013.
7. Karali, E., Bellou, S., **Stellas**, D., Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. *Mol. Cell* 54: 559-572. 2014.
8. Truillet, C., Bouziotis, P., Tsoukalas, C., Sancey, L., Denat, F., Boschetti, F., **Stellas**, D., Anagnostopoulos, C.D., Koutoulidis, V., Moulopoulos, L.A., Lux, F., Perriat, P., and Tellement, O.: Innovative multimodal DOTA/NODA nanoparticles for MRI and PET imaging for tumor detection. *EJNMMI Phys.*, 1: A80. 2014.
9. **Stellas**<sup>#</sup>, D., Souliotis, V., Bekyrou, M., Smirlis, D., Kirsch-Volders, M., Cundari, E., and Kyrtopoulos, S.: Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability. *Mutat. Res.* 769: 59-68. 2014. \*corresponding author
10. **Stellas**, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: Therapeutic effects of an anti-myc drug on mouse pancreatic cancer. *J. Natl. Cancer Inst.* 2014.
11. Truillet, C., Bouziotis, P., Brugiére, J., Martini, M., Sancey, L., Lux, F., Denat, F., Boschetti, F., **Stellas**, D., Anagnostopoulos, C., Koutoulidis, V., Moulopoulos, L., Perriat, P., and Tillement, O.: Ultrasmall particles for Gd-MRI and 68Ga-PET dual imaging. *Contrast Media Mol. Imaging* 10: 309-319. 2014.
12. Karali, E., Bellou, S., **Stellas**, D., Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signaling, mTOR complexes, and the endoplasmic reticulum: towards a role of metabolic sensing in the regulation of angiogenesis. *Mol. Cell Oncol.* 1: e964024. 2014.

13. Galani, A., Tsitsias, V., **Stellas**, D., Psycharis, V., Raptopoulou, C., and Karaliota, A.: Two novel compounds of vanadium and molybdenum with carnitine exhibiting potential pharmacological use. *J. Inorg. Biochem.* 142: 109-117. 2015.
14. Kyrkou, A., **Stellas**, D., Syrrou, M., Klinakis, A., Fotsis, T., and Murphy, C.: Generation of human induced pluripotent stem cells in defined, feeder-free conditions. *Stem Cell Res.* 17: 458-460. 2016.
15. Stivarou\*, T., **Stellas\***, D., Vartzi, G., Thomaidou, D., and Patsavoudi, E.: Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo. *Cancer Biol. Ther.* 17: 799-812. 2016. \*equal contribution
16. Pippa, N., **Stellas**, D., Skandalis, A., Pispas, S., Demetzos, C., Libera, M., Marcinkowski, A., and Trzebicka, B.: Chimeric lipid/block copolymer nanovesicles: physico-chemical and bio-compatibility evaluation. *Eur. J. Pharm. Biopharm.* 107: 295-309. 2016.
17. Kouroupi, G., Taoufik, E., Vlachos, I.S., Tsioras, K., Antoniou, N., Papastefanaki, F., Chroni-Tzartou, D., Wrasidlo, W., Bohl, D., **Stellas**, D., Politis, P.K., Vekrellis, K., Vekrellis, K., Papadimitriou, D., Stefanis, L., Bregestovski, P., Hatzigeorgiou, A.G., Masliah, E., and Matsas, R.: Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. *Proc. Natl. Acad. Sci. USA* 114: E3679-E3688. 2017.
18. Pippa, N., Chronopoulos, D.D., **Stellas**, D., Fernandez-Pacheco, R., Arenal, R., Demetzos, C., and Tagmatarchis, N.: Design and development of multi-walled carbon nanotube-liposome drug delivery platforms. *Int. J. Pharm.* July 7: 528: 429-439. 2017.
19. Bouziotis, P., **Stellas**, D., Thomas, E., Truillet, C., Tsoukalas, C., Lux, F., Tsoதாக, T., Xanthopoulos, S., Paravatou-Petsotas, M., Gaitanis, A., Mouloupoulos, L.A., Koutoulidis, V., Anagnostopoulos, C.D., and Tillement, O.: 68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy. *Nanomedicine (Lond)* Dec 12: 1561-1574. 2017.
20. Matak, A., Lahiri, P., Ford, E., Pabst, D., Kashofer, K., **Stellas**, D., Thanos, D., and Zatloukal, K.: Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer. *Hepatology* 68(3):933-948. 2018
21. Billiard, F., Karaliota, S., Wang, B., **Stellas**, D., Serafimidis, I., Manousopoulou, A., Koutmani, Y., Ninou, E., Golubov, J., DaNave, A., Tsakanikas, P., Xin, Y., Zhang, W., Sleeman, M., Yancopoulos, G.D., Murphy, A.J., Garbis, S.D., Karalis, K., and Skokos, D.: Delta-like ligand-4-notch signaling inhibition regulates pancreatic islet function and insulin secretion. *Cell Rep.* 22: 895-904. 2018.
22. Watson, D.C., Yung, B.C., Bergamaschi, C., Chowdhury, B., Bear, J., **Stellas**, D., Morales-Kastresana, A., Jones, J.C., Felber, B.K., Chen, X., and Pavlakis, G.N.: Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL-15 / Lactadherin complexes. *J Extracell Vesicles.* 28;7(1):1442088. 2018

23. Naziris, N., Pippa, N., **Stellas**, D., Chrysostomou V., Libera, M., Trzebicka, B., Pispas, S., and Demetzos, C.: Development and Evaluation of Stimuli-responsive Chimeric Nanostructures. *AAPS PharmSciTech*. Oct;19(7):2971-2989. 2018
24. Pippa, N., Naziris, N., **Stellas**, D., Massala, C., Zouliati, K., Pispas, S., Demetzos, C., Forsys, A., Marcinkowski, A., Trzebicka, B.: PEO-b-PCL grafted niosomes: the cooperativity of amphiphilic components and their properties in vitro and in vivo. *Colloids and Surfaces B: Biointerfaces* May (177):338-345. 2019
25. Pippa N, Stangel C, Kastanas I, Triantafyllopoulou E, Naziris N, **Stellas**, D., Zhang M, Yudasaka M, Demetzos C, Tagmatarchis N.: Carbon nanohorn/liposome systems: Preformulation, design and in vitro toxicity studies. *Mater Sci Eng C Mater Biol Appl*. Dec; 105:110114. 2019
26. Mameishvili E, Serafimidis I, Iwaszkiewicz S, Lesche M, Reinhardt S, Bölicke N, Büttner M, **Stellas** D, Papadimitropoulou A, Szabolcs M, Anastassiadis K, Dahl A, Theis F, Efstratiadis A, Gavalas A.: Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer. *Proc Natl Acad Sci U S A*. Oct 8;116(41):20679-20688. 2019
27. Karanika E, Soupsana K, Christogianni A, **Stellas** D, Klinakis A, Politou AS, Georgatos S.: Haspin-dependent and independent effects of the kinase inhibitor 5-Iodotubercidin on self-renewal and differentiation. *Sci Rep*. Jan 14;10(1):232. 2020
28. Salvanou, EA., **Stellas**, D., Tsoukalas, C., Mavroidi. B., Paravatou-Petsotas, M., Kalogeropoulos, N., Xanthopoulos, S., Denat ,F., Laurent, G., Bazzi, R., Roux, S., Bouziotis, P. A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225. *Pharmaceutics*. 2020 Feb 21;12(2). pii: E188. doi: 10.3390/pharmaceutics12020188.
29. Bergamaschi, C., Pandit H., Nagy, B., **Stellas**, D., Jensen, S., Bear, J., Cam, M., Valentin, A., Fox, B., Felber BK., Pavlakis, GN. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN- $\gamma$ , CXCL9 and CXCL10. *J Immunother Cancer*. 2020 May;8(1):e000599. doi: 10.1136/jitc-2020-000599.

# : co-corresponding author, \*: equal contribution

*h*-index: 14 (Scopus-Elsevier) Citations: 798

## Meeting Abstracts

1. **Stellas**, D., Villaras, G., Tsiambas, E., Karameris, A., and Patsavoudi, E.: Detection of Heat Shock Protein HSP90 in brain tumors with a new monoclonal antibody, mAb4C5. European Cancer Conference13, Paris, France, October 30-November 3, 2005.
2. **Stellas**, D. and Patsavoudi, E.: Aiming the upgrade of an in vitro laboratory. International Conference on Engineering Education, Athens, Greece, July 8-10, 2005.
3. **Stellas**, D. and Patsavoudi, E.: Inhibition of melanoma cell invasion in vitro with mAb 4C5, a new monoclonal antibody against heat shock protein 90. 57th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, December 9-11, 2005.
4. **Stellas**, D. and Patsavoudi, E.: The monoclonal antibody, mAb 4C5 inhibits B16F10 melanoma cell invasion and metastasis in C57BL/6 mice. 3d Hellenic Anti Carcinogenic Congress, Athens, Greece, April 26-29, 2007.
5. **Stellas**, D. and Patsavoudi, E.: The monoclonal antibody, mAb 4C5 inhibits B16F10 melanoma cell invasion and metastasis. International Conference on Cancer Risk Assessment 2, Thira, Greece, May 25-27, 2007.
6. **Stellas**, D., and Patsavoudi, E.: Extracellular HSP90 interacts with MMP2 and MMP9 and contributes to MDAMB453 human breast cancer cell metastasis in vivo. 33<sup>rd</sup> FEBS Congress, Athens, Greece, June 28-July 3, 2008.
7. **Stellas**, D., Souliotis, V., Bekyrou, M., and Kyrtopoulos, S.: Discovering the molecular components of the B[a]P-induced S- phase arrest. European Environmental Mutagen Society, Cavtat, Croatia, September 21-25, 2008.
8. **Stellas**, D., Souliotis, V.L., Bekyrou, M., Smirlis, D., Kirsch-Voldlers, M., Cundari, E., and Kyrtopoulos, S.A.: B[a]P Induced S-phase arrest: a double-edged sword. High-Throughput Screens in Genome Integrity and Cancer, Oxford, United Kingdom, May 24-27, 2010.
9. Karali, E., Bellou,S., **Stellas**, D., Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. 64th HSBMB Congress, Athens, Greece, December 6-8, 2013.
10. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Polyzos, A.P., Politis, P.K., **Stellas**, D., Xilouri, M., Prodromidou, K., Antoniou, N., Chroni, D., Vekrellis, K., Bregestovski, P., Stefanis, L., Matsas, R.: iPS-derived neural cells from patients with familial Parkinson's disease carrying the A53T  $\alpha$ -synuclein mutation. 26th Meeting of the Hellenic Neuroscience Society jointly with FP7 REGPOT Neurosign: Understanding Brain Function to Treat Dysfunction, Athens, Greece, November 29-December 1, 2013.
11. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Polyzos, A.P., Politis, P.K., **Stellas**, D., Prodromidou, K., Antoniou, N., Chroni, D., Vekrellis, K., Bregestovski, P., Stefanis, L., and Matsas, R.: iPS-derived neural cells from patients with familial Parkinson's disease carrying the A53T  $\alpha$ -synuclein

- mutation. 43rd Annual Meeting of the Society for Neuroscience, San Diego, California, November 9-13, 2013.
12. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Antoniou, N., Chroni, D., Politis, P., **Stellas**, D., Vekrellis, K., Bregestovski, P., Stefanis, L., and Matsas, R.: Cellular stress responses of A53T alpha-synuclein iPS-derived neurons reveal defects in oxidative state, apoptosis and protein degradation. 12<sup>th</sup> Annual Meeting of the International Society for Stem Cell Research, Vancouver, Canada, June 28-21, 2014.
  13. **Stellas**, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. MYC: From Biology to Therapy, La Jolla, California, January 7 - 10, 2015.
  14. **Stellas**, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: A small molecule Myc inhibitor has therapeutic effects on mouse pancreatic and other cancers. American Association for Cancer Research Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015.
  15. Kyrkou, A., Kouroupi, D., Triantafyllidi, E., Katsiboulas, M., **Stellas**, D., Chalepakis, G., Syrrou, M., Klinakis, A., Georgoulis, A., Murphy, C., and Fotsis, T.: Differentiation of human induced pluripotent and mesenchymal stem cells on a 3D scaffold for anterior cruciate ligament regeneration. FEBS, Athens, Greece, October 11-14, 2014.
  16. Karanika, E., Soupsana, K., Christogianni, A., **Stellas**, D., Klinakis, A., Politou, A.S. and Georgatos, S.: KLF4 is overexpressed after treatment with 5-ITu, an inhibitor of Haspin, in mouse embryonic stem cells. FEBS, Athens, Greece, October 11-14, 2014.
  17. Tsoutsis, L., Stratikopoulos, I., Klinakis, A., and **Stellas**, D.: Study of the expression of insulin growth factor I and II (IGFI and IGFI) during the development of mouse embryos. 66<sup>th</sup> Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, December 9-11, 2015.
  18. Giannios, I., Soupsana, K., Chatzantonaki, E., Karakaidos, P., **Stellas**, D., Klinakis, A., Politou, A.S., and Georgatos, S.: Increased dosage of LBR limits the dynamic range of Nanog fluctuations and downregulates Zscan4 in mouse embryonic stem cells. 67<sup>th</sup> Meeting of the Hellenic Society of Biochemistry and Molecular Biology. Ioannina, Greece, November 25-27, 2016.
  19. Markou, M., Kouroupi, D., **Stellas**, D., Murphy, C., Fotsis, T., and Bagli, E.: Generation of mural cells from human pluripotent stem cells. 67<sup>th</sup> Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Ioannina, Greece, November 25-27, 2016.
  20. Morianos, I., Semitekolou, M., **Stellas**, D., and Xanthou, G.: Activin-A potentiates anti-tumor immunity and protects against lung cancer progression in vivo. International Congress of Immunology, Melbourne, Australia, August 21-26, 2016.
  21. Bergamaschi, C., Dimas, K., **Stellas** D., Nagy, B., Jensen, S.M., Fox, B.A., Felber, B.K., and Pavlakakis, G.N.: Treatment with heterodimeric IL-15

- promotes effector T cell infiltration into several tumor types. 5<sup>th</sup> Annual Meeting of the International Cytokine and Interferon Society, Kanazawa, Japan, October 29-November 2, 2017.
22. Bergamaschi, C., Dimas, K., **Stellas** D., Nagy, B., Jensen, S.M., Fox, B.A., Felber, B.K., and Pavlakis, G.N.: Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors. The Society of Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting, National Harbor, Maryland, November 8-12, 2017
  23. **Stellas**, D., Dimas, K., Nagy, B.A., Valentin, A., Felber, B.K., and Pavlakis, G.N.: Heterodimeric interleukin 15 (hetIL-15) treatment decreases primary breast cancer 4T1 tumors and alleviates the metastatic burden. Association for Cancer Research Annual Meeting, Chicago, Illinois, April 14-18, 2018.
  24. Vidali, V., Cournia, Z., Papadimitropoulou, A., **Stellas**, D., Klinakis, A., Couladouros, E., Tamvakopoulos, C. and Efstratiadis, A. Design, synthesis, and efficacy of MYC inhibitors in mouse pancreatic cancer Association for Cancer Research Annual Meeting, Chicago, Illinois, April 14-18, 2018.
  25. Bergamaschi, C., Nagy, B., Jensen, S.M., Dimas, K., Stellas, D., Fox, B.A., Pavlakis, G.N., and Felber, B.K.: Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors: a general method for lymphocyte entry in tumors. 14<sup>th</sup> Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, Rockville, Maryland, April 6, 2018
  26. Watson, D.C., Yung, B.C., Bayik, D., Srivatsan, A., Bergamaschi, C., **Stellas**, D., Felber, B.K., Chen, X., and Pavlakis, G.N.: Engineered extracellular vesicles carrying heterodimeric IL-15: production, characterization and tumor delivery. American Society of Gene and Cell Therapy Annual Meeting, Chicago, Illinois, May 16-19, 2018.
  27. Bergamaschi, C., Nagy, B.A., Jensen S.M., Dimas, K., **Stellas**, D., Fox B.A., Felber, B.K., and Pavlakis, G.N.: Treatment with heterodimeric IL-15 shapes the cytokine milieu of the tumor promoting tumor infiltration by cytotoxic lymphocytes: A general method for lymphocyte entry in tumors. Cytokines Annual Meeting, Boston, October 27-30 2018
  28. **Stellas**, D., Stravokefalou, V., Karaliota, S., Kalen, J., Dimas, K., Kozlov, S., Felber, B.K., and Pavlakis, G.N.: Dose sparing effect and prolonged survival effect of heterodimeric interleukin-15 (IL-15) in combination with gemcitabine in KPC GEM model of pancreatic cancer. 15<sup>th</sup> Annual NIH Graduate Student Research Symposium, Bethesda, Maryland, February 21, 2019
  29. **Stellas**, D., Karaliota, S., Stravokefalou, V., Nagy, B.A., Felber, B.K., and Pavlakis, G.N.: Heterodimeric IL-15 monotherapy results in complete regression of EO771 murine breast tumors through cDC1-lymphocyte interactions and induction of antitumor immunity. American Association for Cancer Research Annual Meeting, Atlanta, Georgia, March 29-April 3, 2019.